OVCA1: Tumor suppressor gene

Current Opinion in Genetics and Development

Volumn 15, Issue 1, 2005, Pages 49-54

  Chen, Chun Ming ^a   Behringer, Richard R ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 2; HISTIDINE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; BIOSYNTHESIS; CATALYSIS; CELL PROLIFERATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MUTANT; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; HETEROZYGOTE; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

FALLOPIA;

EID: 12344267743     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2004.12.006     Document Type: Review

References (35)

1. B.J. Miller, D. Wang, R. Krahe, and F.A. Wright Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions Am J Hum Genet 73 2003 748 767
2. A. Saxena, W.C. Clark, J.T. Robertson, B. Ikejiri, E.H. Oldfield, and I.U. Ali Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas Cancer Res 52 1992 6716 6721
3. N.J. Phillips, M.R. Ziegler, B. Saha, and F. Xynos Allelic loss on chromosome 17 in human ovarian cancer Int J Cancer 54 1993 85 91
4. G.R. Merlo, T. Venesio, A. Bernardi, C.S. Cropp, F. Diella, A.P. Cappa, R. Callahan, and D.S. Liscia Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas Cancer Genet Cytogenet 76 1994 106 111
5. N.J. Phillips, M.R. Ziegler, D.M. Radford, K.L. Fair, T. Steinbrueck, F.P. Xynos, and H. Donis-Keller Allelic deletion on chromosome 17p13.3 in early ovarian cancer Cancer Res 56 1996 606 611
6. D.C. Schultz, L. Vanderveer, D.B. Berman, T.C. Hamilton, A.J. Wong, and A.K. Godwin Identification of two candidate tumor suppressor genes on chromosome 17p13.3 Cancer Res 56 1996 1997 2002
7. H. Konishi, T. Takahashi, K. Kozaki, Y. Yatabe, T. Mitsudomi, Y. Fujii, T. Sugiura, H. Matsuda, T. Takahashi, and T. Takahashi Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers Oncogene 17 1998 2095 2100
8. C.M. Phelan, A. Borg, M. Cuny, D.N. Crichton, T. Baldersson, T.I. Andersen, M.A. Caligo, R. Lidereau, A. Lindblom, and S. Seitz Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters Cancer Res 58 1998 1004 1012
9. D.S. Liscia, R. Morizio, T. Venesio, C. Palenzona, M. Donadio, and R. Callahan Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene Br J Cancer 80 1999 821 826
10. C. Hoff, J. Mollenhauer, B. Waldau, U. Hamann, and A. Poustka Allelic imbalance and fine mapping of the 17p13.3 subregion in sporadic breast carcinomas Cancer Genet Cytogenet 129 2001 145 149
11. N.J. Phillips, M.R. Ziegler, and L.L. Deaven A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3 Cancer Lett 102 1996 85 90
12. L.C. Mattheakis, F. Sor, and R.J. Collier Diphthamide synthesis in Saccharomyces cerevisiae: structure of the DPH2 gene Gene 132 1993 149 154
13. B.G. Van Ness, J.B. Howard, and J.W. Bodley ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products J Biol Chem 255 1980 10710 10716
14. D.C. Schultz, B.R. Balasara, J.R. Testa, and A.K. Godwin Cloning and localization of a human diphthamide biosynthesis-like protein-2 gene, DPH2L2 Genomics 52 1998 186 191
15. T. Ito, T. Chiba, R. Ozawa, M. Yoshida, M. Hattori, and Y. Sakaki A comprehensive two-hybrid analysis to explore the yeast protein interactome Proc Natl Acad Sci USA 98 2001 4569 4574
16. L. Giot, J.S. Bader, C. Brouwer, A. Chaudhuri, B. Kuang, Y. Li, Y.L. Hao, C.E. Ooi, B. Godwin, and E. Vitols A protein interaction map of Drosophila melanogaster Science 302 2003 1727 1736
17. C.M. Chen, and R.R. Behringer Cloning, structure, and expression of the mouse Ovca1 gene Biochem Biophys Res Commun 286 2001 1019 1026
18. C.M. Chen, and R.R. Behringer Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis Genes Dev 18 2004 320 332 In vivo demonstration that Ovca1 is a tumor suppressor gene. In addition, loss of one copy of Ovca1 can modify tumorigenesis in p53 mutant mice, suggesting a genetic interaction between Ovca1 and p53.
19. M.L. Hooper Tumor suppressor gene mutations in humans and mice: parallels and contrasts EMBO J 17 1998 6783 6789
20. D. Malkin Li-Fraumeni syndrome B. Vogelstein K.W. Kinzler The Genetic Basis of Human Cancer edn 2 2002 The McGraw-Hill companies, Inc 387 401
21. X. Xu, W. Qiao, S.P. Linke, L. Cao, W.M. Li, P.A. Furth, C.C. Harris, and C.X. Deng Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis Nat Genet 28 2001 266 271
22. -/- mice Mol Cell Biol 18 1998 4385 4390
23. D.S. Lim, H. Vogel, D.M. Willerford, A.T. Sands, K.A. Platt, and P. Hasty Analysis of ku80-mutant mice and cells with deficient levels of p53 Mol Cell Biol 20 2000 3772 3780
24. C. Kuperwasser, G.D. Hurlbut, F.S. Kittrell, E.S. Dickinson, R. Laucirica, D. Medina, S.P. Naber, and D.J. Jerry Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome Am J Pathol 157 2000 2151 2159
25. M. Schuijer, and E.M. Berns TP53 and ovarian cancer Hum Mutat 21 2003 285 291
26. C.M. Chen, J.L. Chang, and R.R. Behringer Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts Oncogene 23 2004 7722 7725 The authors describe a mouse ovary transplantation system used to study cancer formation. Homozygous p53 mutant ovaries develop hemangiosarcomas rather than carcinoma.
27. W.Y. Chen, X. Zeng, M.G. Carter, C.N. Morrell, R.W. Chiu Yen, M. Esteller, D.N. Watkins, J.G. Herman, J.L. Mankowski, and S.B. Baylin Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors Nat Genet 33 2003 197 202 In vivo demonstration that Hic1, which resides directly adjacent to Ovca1, is also a tumor suppressor gene, suggesting that allelic loss of both loci may influence tumorigenesis. No ovarian tumors were reported. Interestingly, there was methylation in the promoters of the wild type allele of Hic1 heterozygotes, suggesting an epigenetic suppression mechanism for Hic1 in cancer.
28. A. Atalay, T. Crook, M. Ozturk, and I.G. Yulug Identification of genes induced by BRCA1 in breast cancer cells Biochem Biophys Res Commun 299 2002 839 846
29. M.M. Wales, M.A. Biel, W. el Deiry, B.D. Nelkin, J.P. Issa, W.K. Cavenee, S.J. Kuerbitz, and S.B. Baylin p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 Nat Med 1 1995 570 577
30. S. Liu, and S.H. Leppla Retroviral insertional mutagenesis identifies a small protein required for synthesis of diphthamide, the target of bacterial ADP-ribosylation toxins Mol Cell 12 2003 603 613 The authors demonstrate that KTI11/DESR1 function participates in the first step of the diphthamide biosynthesis pathway together with yeast DPH2. In addition, KTI11/DESR1 is involved in the Elongator complex of RNA pol II holoenzyme, suggesting KTI11/DESR1 is required for multiple cellular functions.
31. F. Frohloff, L. Fichtner, D. Jablonowski, K.D. Breunig, and R. Schaffrath Saccharomyces cerevisiae Elongator mutations confer resistance to the Kluyveromyces lactis zymocin EMBO J 20 2001 1993 2003
32. L. Fichtner, and R. Schaffrath KTI11 and KTI13, Saccharomyces cerevisiae genes controlling sensitivity to G1 arrest induced by Kluyveromyces lactis zymocin Mol Microbiol 44 2002 865 875
33. L. Fichtner, D. Jablonowski, A. Schierhorn, H.K. Kitamoto, Rtark MJR, and R. Schaffrath Elongator's toxin-target (TOT) function is nuclear localization sequence dependent and suppressed by post-translational modification Mol Microbiol 49 2003 1297 1309 Using the TAP-tag technique, the authors demonstrated that KTI11 can form a complex with the Elongator subunits (Tot1/Elp1, Tot2/Elp2 and Tot3/Elp3), Yil103W, DPH2 and translation elongation factor, suggesting that KTI11 may functionally link Elongator function and the diphthamide biosynthesis pathway in translation. The authors also showed that dph2 and yil103w mutants were partially resistant to zymocin treatment, implying that the DPH2 gene family may connect the Elongator's function and translation.
34. N. Anand, S. Murthy, G. Amann, M. Wernick, L.A. Porter, I.H. Cukier, C. Collins, J.W. Gray, J. Diebold, D.J. Demetrick, and J.M. Lee Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer Nat Genet 31 2002 301 305
35. S. Liu, G.T. Milne, J.G. Kuremsky, G.R. Fink, and S.H. Leppla Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2 Mol Cell Biol 24 2004 9487 9497